David W (@rn_flex) header
David W (@rn_flex) profile picture

Primary care NP, lover of glucagon agonism, incretin nerd, photographer, mountain lover, coonhound rescuer

Primary care land
Joined October 2021
Photo by David W (@rn_flex)Photo by David W (@rn_flex)Photo by David W (@rn_flex)Photo by David W (@rn_flex)Photo by David W (@rn_flex)Photo by David W (@rn_flex)Photo by David W (@rn_flex)Photo by David W (@rn_flex)Photo by David W (@rn_flex)Photo by David W (@rn_flex)
1/10 #NephJC #TenPostNephJC. #NephTwitter 📺 Video Decision Support and Advance Care Planning in Older Adults with Advanced Kidney Disease ⚖️Can a video decision aid help patients with dialysis decisions? Read the article 👇 VIDEO KD 10.1001/jamainternmed.2026.5989
2
10
13
1,068
$NVO $lly This is potency data from Eloralintide and zenagamtide early publications. Both molecules were compared to cagrilintide in their respective papers, the cross-paper fold relationships hold to within a factor of ~2x. So cagrilintide and petrelintide look pretty similar on this basis I have been wondering why zena appears so uniquely toxic. Zenagamtide has low potency overall at any ctr family receptor and is the least selective between amyr1 and ctr. But it has full potency at glp-1. Probably part of why its so toxic, they are hitting glp-1 so hard to get a small amyr1 benefit? Besides the short t1/2 (3.5 days) which also means I have to acutely spike the concentration to get sufficient coverage for the week. I also wonder what the effect is of having a single large molecule as opposed to cagrilintide+semaglutide which can distribute differently. Basically every single thing about this peptide seems badly designed.
3
2
11
2,629
David W retweeted
🔔Elora+Tzp Phase 2 T2D was presented at Obesity Week today. This was presented at EASD 2026 earlier this fall, but they gave us more background today. INTRO ▪️Set the stage by reviewing the Eloralintide’s potency at the AMY1R receptor vs both CTR and AMY3R, establishing it as a selective amylin agonist ▪️Reviewed Elora’s 48 week Phase 2 performance on its own (up to 20% WL) and the recent P1 Elora + Tirz data (up to 29% WL at 31 weeks) - both in obesity without T2D ▪️Prior best performance in T2D for weight-loss was 16% at 72 weeks (using tirzepatide) RESULTS (48 weeks) - Efficacy estimand ▪️Elora alone - 8-12% WL, 1.1-1.4% A1C reduction ▪️EloraTZP (3/6mg Elora) - 19-23% WL, 2.6-2.9% A1C reductio 💥NEW INFO💥 ▪️BMI targets: On highest EloraTzp dose, 46% reached BMI <= 25 (Baseline BMI of 40) 😲 ▪️AE DC reasons🙌: 1 EloraTzp + 1 Tzp for weight reduction, 4 EloraTzp for decreased appetite, 5 EloraTzp for nausea, 2 EloraTzp vomiting ▪️Pulse rates dropped on Elora alone, rose on TZP, and were in the middle for EloraTzp ▪️Body composition changes: Fat loss index (% of WL from fat): Elora alone - 60-66%, EloraTzp (3/6mg) - ~70%, Tzp + Add on Elora 60% ▪️Prevalence of side effects ▪️Prevalence and severity of fatigue
7
5
34
2,890
1/10 #NephJC #TenPosts 🫘 Intermittent HD or continuous RRT for critically ill patients with AKI? ⚖️ For years, trials suggested similar outcomes. Does the choice of modality affect survival? 💥 The ICRAKI trial challenges previous evidence nejm.org/doi/10.1056/NEJMoa2…
1
13
1
19
1,896
IHD vs CRRT again. ICRAKI was stopped early due to higher mortality with IHD. Real signal or truncation artifact? And was IHD given the way we'd give it to a patient on vasopressors? #NephJC #nephtwitter ✍️ By @rn_flex @DivyaveerSSNeph nephjc.com/news/icraki11126
1
25
2
49
4,194
If someone miraculously invented a drug that: - successfully reversed obesity and most of its associated diseases - improved longevity - decreased the long term health costs ….and it was NOT covered by health insurance, …. - then what would be the use of health insurance?
14
11
2
97
5,667
Managing iron-deficiency anemia is a challenge in CKD. This randomized trial in #ASNCJASN found that adding lactoferrin to oral iron improved hemoglobin and iron status more than iron alone, suggesting a potentially accessible treatment strategy. kidney.pub/CJASN11204
17
1
44
3,945
David W retweeted
😲 The most shocking info that David (@rn_flex) highlighted in this piece was the difference in the A1C reductions between CagriSema and EloraTZP. ▪️The two amylins clearly have very different efficacy for A1C reduction. In REIMAGINE 2, Cagrilintide 2.4 mg showed a -0.8 reduction in A1C (efficacy estimand), while Elora showed reductions of -1.06 to -1.42 on its own in its T2D P2. ▪️All 5 EloraTZP arms had at least 90%% of patients hitting an A1C < 7%, and two arms had 100%, compared to 82% for CS 2.4/2.4mg. ▪️4/5 of the EloraTZP arms had 66-77% of patients reach normal glycemia (A1C < 5.7%), and the 5th (the lowest dose arm) hit 45%, while CS 2.4/2.4mg only had 20.6% achieve normal glycemia. ▪️Baseline A1C were 8.2% for REIMAGINE 2, and 8.14% for the EloraTZP P2. The normal glycemia data for CS is pulled from their ADA presentation. I could not find it in the REIMAGINE-2 paper. Also added the TRIUMPH-2 A1C data for retatrutide, but I should note that the baseline A1C was 7.7%.
🔥 It feels foolish to post TWO @rn_flex articles in one day, but here we are. ▪️GREAT REVIEW of the whirlwind that was Tuesday and Wednesday of EASD 2026, plus a pretty great synopsis of how wild the last 10 years have been in GLP-1s ▪️Retatrutide TRIUMPH-1 and -2 and Elora Tirz P1 & T2D P2 ▪️If you want to be excited about future treatment *possibilities*, this is a great review of retatrutide and eloralintide + tirzepatide ▪️Caveat: There’s definitely still work to do in optimizing tolerability and safety, and figuring out how to report all of this back to trial readers (docs, investors, and patients) Humor: Pretty sure there’s a dungeon and dragons/dice-based role playing game reference in there 🤦‍♀️, plus a classic Jurassic Park one as well 🦕. [Yes, I’m admitting to playing a weekend or two of D&D in my foolish college years.] the-incretins.beehiiv.com/p/…
2
5
24
2,555
David W retweeted
🔥 It feels foolish to post TWO @rn_flex articles in one day, but here we are. ▪️GREAT REVIEW of the whirlwind that was Tuesday and Wednesday of EASD 2026, plus a pretty great synopsis of how wild the last 10 years have been in GLP-1s ▪️Retatrutide TRIUMPH-1 and -2 and Elora Tirz P1 & T2D P2 ▪️If you want to be excited about future treatment *possibilities*, this is a great review of retatrutide and eloralintide + tirzepatide ▪️Caveat: There’s definitely still work to do in optimizing tolerability and safety, and figuring out how to report all of this back to trial readers (docs, investors, and patients) Humor: Pretty sure there’s a dungeon and dragons/dice-based role playing game reference in there 🤦‍♀️, plus a classic Jurassic Park one as well 🦕. [Yes, I’m admitting to playing a weekend or two of D&D in my foolish college years.] the-incretins.beehiiv.com/p/…
2
1
18
3,568
David W retweeted
Let’s look at this, shall we? ▪️The standards for inclusion only appear to require a SINGLE GLP-1 injectable SCRIPT (not a fill) prior to switch. So some people in this might not have ever taken an injectable, if they ran into insurance or cost issues. ▪️41% of those switched from Zepbound had 2.5mg as their last script before switching. Thats just the intro dose and not approved for weight loss efficacy. ▪️69% of those switching from injectable Wegovy were on 1mg or lower for their last script before switching. 1.7mg is the first dose approved for weight loss efficacy. ▪️Mean BMI change over 3 months was 1.4 and mean loss was 4kg (8.8lbs). ▪️That may be *statistically* significant, but is it that stage sort of significance patients are expecting when you say “significantly”? ▪️They don’t break out results by starting treatment AT ALL.
#PRESS: What happened when people switched from weight-loss injections to a pill? Learn more about the findings, presented at EASD 2026, in our press release: novonordisk.com/content/nnco…
3
2
1
20
3,963
Certainly its becoming less practical, and much less informative, to try to compare novel therapy to something below the best standard of care. Drop in rates of GLP-1 and the rising attrition rates in placebo confound effect sizes, make studies less interpretable and demonstrate patient need. Since the approved molecules are now abundant, should be standard of care for obesity management, and increasingly reimbursed - your point is a good one.
I think we’ve reached the point where it’s unethical to compare against a placebo
10
6
3
81
15,137
Hey #NephJC 👋 Checkout the VA by @DivyaveerSSNeph This week we're looking at steroid weaning strategies in adults with podocytopathies (MCD/FSGS). 💊Steroids: easy to start but hard to stop. #NephTwitter nephjc.com/news/starttrial
20
3
31
3,676
Replying to @Roche
@Roche notches impressive P2 data for the GLP-1R-GIPR co-co-agonist Enicepatide #T2D #weightloss roche.com/media/releases/med…
2
17
1
89
6,481
David W retweeted
🚨 The Novo Nordisk Foundation funded a very interesting trial, REACT, that is being presented this weekend as part of #ESC2026. The related paper is: “Prevalence of Silent Atherosclerosis across Adult Life.” It found, that among adults with no known atherosclerotic cardiovascular disease: ▪️Atherosclerosis was identified in 57.1% of participants, with presence varying by age and sex ▪️In the 18-29 group, silent atherosclerosis was detectable 8.7% of men and 6.7% of women ▪️This increased to 34.6% of men and 21.3% of women 30 to 39 years old ▪️By 60-70, only 1.9% of men and 8.1% of women had no plaque detected in any examined territory Their imaging looked for atherosclerosis (plaque) in both coronary and peripheral arteries. I believe this is an attempt to start laying the ground work for coverage of semaglutide and CagriSema as a preventative CVD measure (prior to an adverse CV event) in a broader population, just as Medicare Bridge and BALANCE are enabling coverage for seniors with pre-diabetes, even though that’s not actually an FDA indication for weight loss GLP-1s at this time.
4
4
4
43
6,272
1/10 #NephJC #TenPostNephJC #NephTwitter Can just 4 doses of an SGLT2i prevent AKI after cardiac surgery? The MERCURI-2 trial put dapagliflozin to the test. But is the benefit a treat or a trick?🫀💊 Read the article 👇 pubmed.ncbi.nlm.nih.gov/4253…
1
10
3
17
2,974
Here’s our (@NephJC’s) 🔥 fiery review of the MERCURI-2 trial ! What to say, the limitations seem limitless ! 😅 Probably one of the first trials I’ve read where Urine output takes up more space and value than Creatinine in the AKI equation. Summary by @rn_flex and @DrBarbaTeba (the girl with the 🐈‍⬛s) @DrPallaviPrasad @brian_rifkin @CristinaDeReins @jmteakell @assad_sm @kidney_boy @hswapnil @dra_miliflores
1
5
16
2,804
Excited for SGLT2 inhibitors to prevent AKI in CV surgery patients? So were we... until we got past the title. This week we're talking about "that JAMA paper "🙃 #NephJC #NephTwitter Here's the VA by @ManoleaA nephjc.com/news/2026/8/17/me…
2
14
2
31
3,342